A screening assay for detecting CD8+ cell non-cytotoxic anti-HIV responses.
The rate of HIV-1 disease progression is influenced by several factors that include pathogen and host genetic variations and the quality of antiviral immune responses. The CD8+ cell non-cytotoxic antiviral response (CNAR) substantially suppresses HIV replication in CD4+ cells and is positively associated with an asymptomatic clinical state. Traditionally, the measurement of CNAR has required several culture procedures and costly reagents. Here we report the development and validation of a screening assay for detection of CNAR that accurately identifies individuals benefiting from this response. Use of the CNAR screening assay should facilitate the evaluation of this important immune parameter in studies of HIV pathogenesis, resistance to infection, and vaccine development.
Killian
M Scott
MS
AIDS Research Institute and Department of Medicine, University of California San Francisco, San Francisco, CA 94143, United States.
Ng
Sharon
S
Mackewicz
Carl E
CE
Levy
Jay A
JA
D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D003602:Cytotoxicity, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D005434:Flow Cytometry / Q000379:methods; D006678:HIV / Q000276:immunology* / Q000502:physiology; D015658:HIV Infections / Q000175:diagnosis / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000821:virology; D018655:Lymphocyte Count / Q000379:methods; D008212:Lymphocyte Depletion; D008403:Mass Screening / Q000379:methods*; D014779:Virus Replication / Q000502:physiology